Evotec (EVO) vs Pacira BioSciences (PCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Pacira BioSciences (PCRX) has outperformed Evotec (EVO) over the past year, gaining 55.4% versus a loss of 60.6%. Over five years, PCRX leads with a -52.6% price change compared with -93.1% for EVO. Pacira BioSciences is the larger company by market cap ($1.45 billion vs $558.0 million), about 2.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVO | PCRX |
|---|---|---|
| Share price | $1.57 | $36.39 |
| Market cap | $557.96M | $1.45B |
| 1-day change | -2.48% | +44.40% |
| YTD return | -49.03% | +40.61% |
| 1-year return | -60.55% | +55.45% |
| 5-year return | -93.05% | -52.63% |
| P/E ratio (TTM) | — | 103.97 |
| Forward P/E | — | 10.52 |
| EPS (TTM) | $-0.64 | $0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.27 | $36.40 |
| 52-week low | $1.50 | $18.80 |
| Distance from 52-week high | -63.23% | -0.03% |
| Analyst consensus | none | buy |
| Avg. price target upside | +164.97% | -17.26% |
| Average volume | 103.98K | 588.87K |
| Shares outstanding | 355.39M | 39.86M |
| Employees | 4,461 | 825 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Pacira BioSciences is about 2.6 times larger than Evotec by market value ($1.45B vs $557.96M).
- PCRX has outperformed EVO by 116.0 percentage points over the past year.
About Evotec
EVO stock →Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics.
Health Care · Biotechnology: Pharmaceutical Preparations · 4,461 employees
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
EVO vs PCRX FAQ
Which is bigger, Evotec or Pacira BioSciences?
Pacira BioSciences (PCRX) is larger, with a market capitalization of $1.45B compared with $557.96M for Evotec (EVO).
Which stock has performed better over the past year, EVO or PCRX?
PCRX returned +55.45% over the past 12 months, compared with -60.55% for EVO (price return, excluding dividends). Past performance does not predict future results.
Are Evotec and Pacira BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.